Early Breast Cancer

Oncology
3
Pipeline Programs
6
Companies
4
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
1
1
Early DiscoveryClinical DevelopmentMarket

On Market (1)

Approved therapies currently available

U
NEOSARApproved
cyclophosphamide
Unknown Company
injection1982

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Roche
RocheSTAVANGER NORWAY, Norway
2 programs
1
1
CyclophosphamidePhase 31 trial
GiredestrantPhase 21 trial
Active Trials
NCT04436744Completed221Est. Nov 2021
NCT03493854Completed500Est. Jun 2023
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
Electronic Study for Anastrozole Pharmacovigilance EvaluationN/A1 trial
Active Trials
NCT00558168Completed1,850Est. Jul 2008
Alliance Pharmaceuticals
1 program
Endocrine therapy interruptionN/A1 trial
Active Trials
NCT02308085Active Not Recruiting518Est. Dec 2028

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
RocheCyclophosphamide
RocheGiredestrant
Alliance PharmaceuticalsEndocrine therapy interruption
AstraZenecaElectronic Study for Anastrozole Pharmacovigilance Evaluation

Clinical Trials (4)

Total enrollment: 3,089 patients across 4 trials

NCT03493854RocheCyclophosphamide

A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer

Start: Jun 2018Est. completion: Jun 2023500 patients
Phase 3Completed
NCT04436744RocheGiredestrant

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer)

Start: Sep 2020Est. completion: Nov 2021221 patients
Phase 2Completed
NCT02308085Alliance PharmaceuticalsEndocrine therapy interruption

Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive Breast Cancer

Start: Dec 2014Est. completion: Dec 2028518 patients
N/AActive Not Recruiting
NCT00558168AstraZenecaElectronic Study for Anastrozole Pharmacovigilance Evaluation

Electronic Study for Anastrozole Pharmacovigilance Evaluation

Start: Jan 2004Est. completion: Jul 20081,850 patients
N/ACompleted

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
1h ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
1h ago

Office Administrator

SystImmune
1h ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
1h ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
1h ago

Working Student Active Sourcing Support (m/f/d)

Mindpeak
Hamburg
1h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
6 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)